Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Johnson JA, et al. Among authors: gage bf. Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4. Clin Pharmacol Ther. 2017. PMID: 28198005 Free PMC article.
Management and dosing of warfarin therapy.
Gage BF, Fihn SD, White RH. Gage BF, et al. Am J Med. 2000 Oct 15;109(6):481-8. doi: 10.1016/s0002-9343(00)00545-3. Am J Med. 2000. PMID: 11042238 Review.
Use of pharmacogenetics to guide warfarin therapy.
Voora D, McLeod HL, Eby C, Gage BF. Voora D, et al. Among authors: gage bf. Drugs Today (Barc). 2004 Mar;40(3):247-57. doi: 10.1358/dot.2004.40.3.820088. Drugs Today (Barc). 2004. PMID: 15148533
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Voora D, et al. Among authors: gage bf. Thromb Haemost. 2005 Apr;93(4):700-5. doi: 10.1160/TH04-08-0542. Thromb Haemost. 2005. PMID: 15841315
Pharmacogenetics-based coumarin therapy.
Gage BF. Gage BF. Hematology Am Soc Hematol Educ Program. 2006:467-73. doi: 10.1182/asheducation-2006.1.467. Hematology Am Soc Hematol Educ Program. 2006. PMID: 17124101 Review.
Genetic-based dosing in orthopedic patients beginning warfarin therapy.
Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF. Millican EA, et al. Among authors: gage bf. Blood. 2007 Sep 1;110(5):1511-5. doi: 10.1182/blood-2007-01-069609. Epub 2007 Mar 26. Blood. 2007. PMID: 17387222 Free PMC article. Clinical Trial.
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Gage BF, et al. Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27. Clin Pharmacol Ther. 2008. PMID: 18305455 Free PMC article.
Estimation of the warfarin dose with clinical and pharmacogenetic data.
International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. International Warfarin Pharmacogenetics Consortium, et al. Among authors: gage bf. N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. N Engl J Med. 2009. PMID: 19228618 Free PMC article.
186 results